New York (Reuters) – According to insiders, the Swiss pharmaceutical company Novartis is in advanced talks to take over the biotech company Morphosys.
Novartis prevailed against the drug manufacturer Incyte, which also had its eye on Morphosys, the Reuters news agency learned from two people familiar with the matter on Monday. However, it is not yet certain that a transaction will take place. No comment was initially available from Novartis, Morphosys and Incyte.
(Report by David Carnevali, written by Patricia Weiß. Edited by Olaf Brenner. If you have any questions, please contact our editorial team at [email protected] (for politics and economics) or [email protected] (for companies and markets).)
Selected leveraged products on MorphoSys
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on MorphoSys
The leverage must be between 2 and 20
Advertising